Santoro N, Waldbaum A, Lederman S, et al. - Since oral fezolinetant vs placebo decreased frequency as well as the severity of menopausal vasomotor symptoms (VMS) in the primary analysis of the phase 2b VESTA study, therefore, researchers performed this secondary analysis to determine how responder rates and patient-reported outcomes (PROs) could be impacted by fezolinetant. Postmenopausal women with moderate/severe VMS enrolled in this 12-week, double-blind study were randomly assigned to fezolinetant 15, 30, 60, or 90 mg BID or 30, 60, or 120 mg QD or placebo. Overall 356 women were randomized, 352 were treated and examined. Findings revealed higher responder rates in correlation with treatment with oral fezolinetant vs placebo. Oral fezolinetant conferred larger improvements in QoL as well as other PRO measures, including a decrease in VMS-related interference with daily life.